Fertility News and Research

RSS

Boston IVF The Maine Center opened to offer full range of infertility and reproductive health services

Boston IVF, a leading medical practice providing specialized infertility treatment since 1986, is expanding its patient care services in Maine and has opened Boston IVF The Maine Center, offering local patients state-of-the-art care closer to home.

25 Feb 2010

Ovarian transplant: A viable method for fertility treatment

For the first time, a woman has given birth to two children after her fertility was restored using transplants of ovarian tissue that had been removed and frozen during her cancer treatment and then restored once she was cured.

25 Feb 2010

Advanced ovarian cancer: Avastin-chemotherapy combination followed by Avastin alone improves PFS

Genentech, Inc., a wholly owned member of the Roche Group, today announced that a Phase III study showed the combination of Avastin® (bevacizumab) and chemotherapy followed by maintenance use of Avastin alone increased the time women with previously untreated advanced ovarian cancer lived without the disease worsening (progression-free survival or PFS), compared to chemotherapy alone. A preliminary assessment of safety noted adverse events previously observed in pivotal trials of Avastin.

25 Feb 2010

Frozen/thawed ovarian tissue transplant: Woman has two children from separate pregnancies

24 Feb 2010

Women who become pregnant with single foetus after IVF/ICSI have increased risk of stillbirth

Women who become pregnant with a single foetus after in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) have an increased risk of a stillbirth, according to new research out today (Wednesday).

24 Feb 2010

Genentech's Avastin combination Phase III study in advanced stomach cancer does not meet primary endpoint

Genentech, Inc., a wholly owned member of the Roche Group, today announced that a Phase III study (AVAGAST) did not meet its primary endpoint of showing Avastin® (bevacizumab) plus Xeloda® (capecitabine) or 5-FU and cisplatin chemotherapy extended the lives of people with inoperable or advanced stomach (gastric) cancer, compared to chemotherapy alone.

23 Feb 2010

Conference for Young Women Affected by Breast Cancer: 10th anniversary

2010 marks the 10th anniversary of the only international conference dedicated to the critical issues of young breast cancer survivors and those who care about them. Nearly 1,000 young breast cancer survivors, caregivers and medical professionals from around the world are expected to attend the 10th Annual Conference for Young Women Affected by Breast Cancer, to be held Friday, Feb. 26-Sunday, Feb. 28 at the Sheraton Atlanta Hotel in Atlanta, Ga.

19 Feb 2010

10th Annual Conference for Young Women Affected by Breast Cancer

Young women diagnosed with breast cancer are uniquely impacted by issues often not faced by older women. Breast cancer is often detected at later stages, increasing diagnoses of more advanced cancers. The impact of cancer treatment on fertility, body image, financial challenges, and slightly higher mortality rates are significant concerns for this population.

19 Feb 2010

UCSF team: NIH ethics guidelines for embryonic stem cell research need to be modified

A UCSF team, led by bioethicist Bernard Lo, MD, recommends that the National Institutes of Health ethics guidelines for embryonic stem cell research be modified to better protect the rights of individuals donating egg or sperm to patients undergoing in vitro fertilization.

19 Feb 2010

Medical experts convene to discuss emotional and medical issues of young breast cancer survivors

One in eight women diagnosed with breast cancer is younger than 45 when diagnosed, yet their emotional and medical concerns are different than those of women over age 45, as is the impact of their diagnosis on family, friends, partners, colleagues and children.

18 Feb 2010

Phase III data reveals potential of Merck’s GARDASIL in preventing HPV and HPV-related cancers

Merck & Co., Inc. announced today that in new Phase III data, GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] was 77.5 percent (95 percent CI: 39.6, 93.3) efficacious against anal intraepithelial neoplasia (AIN) associated with human papillomavirus (HPV) types 6, 11, 16 and 18 in 16-to-26 year-old men who have sex with men. The data were presented at the European Research Organization on Genital Infection and Neoplasia (EUROGIN) conference in Monte Carlo, Monaco.

18 Feb 2010

Merck announces global sales of $27.4 billion for full-year 2009

Merck & Co., Inc. today announced financial results for the fourth quarter and the full year of 2009 which include the results of legacy Schering-Plough operations from the close of the merger on Nov. 3, 2009 through Dec. 31, 2009.

16 Feb 2010

'Fertility chip' to accurately count spermatozoa in sperm

A new 'fertility chip', developed by researchers at the University of Twente's MESA+ Institute for Nanotechnology, can accurately count spermatozoa in sperm. This is an important step towards the development of a compact device for reliable 'pre-scanning' of male fertility. The researchers are publishing the invention of the chip in the scientific journal Lab on a Chip.

16 Feb 2010

Infertility patients from across GTA demand government-funded IVF

Infertility patients from across the GTA gathered at Queen's Park this morning to demand government-funded in vitro fertilization (IVF). Larger than life children's building blocks on the steps of the provincial legislative building spelled out the $550 million the Ontario Expert Panel on Infertility and Adoption says the province could save in long term health care and social services costs by funding IVF.

16 Feb 2010

RI-MUHC and McGill University teams receive $5M CIHR grant for environmental and reproductive health studies

Two teams from the Research Institute of the McGill University Health Centre (RI-MUHC) and McGill University received significant support from the Canadian Institutes of Health Research (CIHR) amounting to $5 million over five years.

15 Feb 2010

IntegraMed America prices common stock offering at $7.50 per share

IntegraMed America, Inc. today announced that it has priced a public offering of 2,500,000 shares of its common stock at a price to the public of $7.50 per share, of which 2,000,000 shares are being offered through the underwriters named below and 500,000 shares are being offered directly by IntegraMed to IAT Reinsurance Company Ltd., IntegraMed’s largest stockholder.

12 Feb 2010

Vitrolife announces 14% increase in sales for fourth-quarter 2009

Sales increased by 14 percent during the fourth quarter and amounted to SEK 67 (59) million. Calculated in local currency growth was 15 percent. Sales for the year amounted to SEK 275 (225) million, corresponding to an increase of 22 percent. Calculated in local currencies growth was 10 percent.

10 Feb 2010

New Success Prime IVF Program launched

Reproductive Partners Medical Group, Inc. announces the launch of the Success Prime IVF Program, an IVF money back guarantee for best-case patients.

10 Feb 2010

New Multi-Cycle program reduces risk of infertility treatment for older mothers

Fertility experts at the Reproductive Science Center of the Bay Area (RSC) announced they have launched a new program from IntegraMed geared toward easing the risk of infertility treatment for qualified women of ages 49 and younger who want to use their own eggs in order to achieve pregnancy.

10 Feb 2010

Physical Activity Innovations named ‘Bluetooth Innovator of the Year’ for 2009

The Bluetooth SIG has awarded Edward Sazonov, Physical Activity Innovations LLC, the title of Bluetooth Innovator of the Year for 2009. Sazonov received this recognition at the official award ceremony held in-line with the Wearable Technologies Show at ispo 2010, the world’s largest trade show for sporting goods.

9 Feb 2010

Fertility News and Research

Boston IVF The Maine Center opened to offer full range of infertility and reproductive health services

Ovarian transplant: A viable method for fertility treatment

Advanced ovarian cancer: Avastin-chemotherapy combination followed by Avastin alone improves PFS

Frozen/thawed ovarian tissue transplant: Woman has two children from separate pregnancies

Women who become pregnant with single foetus after IVF/ICSI have increased risk of stillbirth

Genentech's Avastin combination Phase III study in advanced stomach cancer does not meet primary endpoint

Conference for Young Women Affected by Breast Cancer: 10th anniversary

10th Annual Conference for Young Women Affected by Breast Cancer

UCSF team: NIH ethics guidelines for embryonic stem cell research need to be modified

Medical experts convene to discuss emotional and medical issues of young breast cancer survivors

Phase III data reveals potential of Merck’s GARDASIL in preventing HPV and HPV-related cancers

Merck announces global sales of $27.4 billion for full-year 2009

'Fertility chip' to accurately count spermatozoa in sperm

Infertility patients from across GTA demand government-funded IVF

RI-MUHC and McGill University teams receive $5M CIHR grant for environmental and reproductive health studies

IntegraMed America prices common stock offering at $7.50 per share

Vitrolife announces 14% increase in sales for fourth-quarter 2009

New Success Prime IVF Program launched

New Multi-Cycle program reduces risk of infertility treatment for older mothers

Physical Activity Innovations named ‘Bluetooth Innovator of the Year’ for 2009

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News